Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Posted by on Feb 27, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The aim of this study was to evaluate high-dose (HD) methotrexate (MTX; Trexall) alone and in combination with other therapies for the treatment of primary central nervous system (CNS) lymphoma (PNCSL). The study found that HD-MTX in combination with other chemotherapies was most effective for these patients. Some background...

Read More

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

Posted by on Feb 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate if rituximab (Rituxan), bendamustine (Treanda), and mitoxantrone (Novantrone) or R-BM followed by rituximab consolidation was a safe and effective treatment in older patients with follicular lymphoma (FL). The authors concluded that this treatment provided durable responses and was well tolerated in...

Read More

Is rituximab maintenance effective long-term for follicular lymphoma after an autologous stem cell transplant?

Is rituximab maintenance effective long-term for follicular lymphoma after an autologous stem cell transplant?

Posted by on Feb 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors reviewed rituximab (Rituxan) maintenance (RM) therapy in patients with relapsed follicular lymphoma (FL) treated with an autologous stem cell transplant (ASCT). The study found that RM after ASCT delayed FL relapse after a 12-year follow up. Some background Rituximab and chemotherapy have improved the outcomes of...

Read More

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated different rituximab schedules in patients with follicular lymphoma (FL) and reported their long-term treatment outcomes. The data showed that rituximab treatment alone on a standard schedule improves the long-term outcomes of these patients. Some background Follicular lymphoma (FL) is a type of non-Hodgkin...

Read More

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether lenalidomide maintenance therapy after intensive chemoimmunotherapy and first-line autologous hematopoietic stem-cell transplantation (AHSCT) improved the outcomes of patients with mantle cell lymphoma (MCL). The data showed that lenalidomide maintenance after AHSCT improved the survival without...

Read More

Evaluating the safety and effectiveness of geptanolimab unresponsive peripheral T cell lymphoma

Evaluating the safety and effectiveness of geptanolimab unresponsive peripheral T cell lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study assessed the effectiveness and safety of geptanolimab (GB226) in relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL). The authors concluded that geptanolimab showed promising activity and manageable safety in these patients. Some background Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin...

Read More

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

Posted by on Jan 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the effect of chemotherapy dose intensity on outcomes for patients with adult T-cell leukemia/lymphoma.  This study concluded that higher chemotherapy dose intensity improves outcomes for these patients.  Some background Adult T-cell leukemia/lymphoma (ATL) is an aggressive blood cancer. It can...

Read More